W Brinjikji1,2,3, T Krings3, M H Murad4, A Rouchaud5, D Meila6,7. 1. From the Departments of Radiology (W.B.) brinjikji.waleed@mayo.edu brinjikji.waleed@gmail.com. 2. Neurosurgery, (W.B.). 3. Division of Neuroradiology and Neurosurgery (W.B., T.K.), University of Toronto, Toronto Western Hospital and University Health Network, Toronto, Ontario, Canada. 4. Center for the Science of Healthcare Delivery (M.H.M.), Mayo Clinic, Rochester, Minnesota. 5. Neuroradiology Service (A.R.), Centre Hospitalier Universitaire Bicêtre, Le Kremlin Bicêtre, France. 6. Department of Radiology and Neuroradiology (D.M.), Klinikum Duisburg, Duisburg, Germany. 7. Department of Diagnostic and Interventional Neuroradiology (D.M.), Medical School Hannover, Hannover, Germany.
Abstract
BACKGROUND: Outcomes after endovascular embolization of vein of Galen malformations remain relatively poorly described. PURPOSE: We performed a systematic review of the literature to determine outcomes and predictors of good outcomes following endovascular treatment of vein of Galen malformations. DATA SOURCES: We used Ovid MEDLINE, Ovid Embase, and the Web of Science. STUDY SELECTION: Our study consisted of all case series with ≥4 patients receiving endovascular treatment of vein of Galen malformations published through January 2017. DATA ANALYSIS: We studied the following outcomes: complete/near-complete occlusion rates, technical complications, perioperative stroke, perioperative hemorrhage, technical mortality, all-cause mortality, poor neurologic outcomes, and good neurologic outcomes. Outcomes were stratified by age-group (neonate, infant, child). A random-effects meta-analysis was performed. DATA SYNTHESIS: A total of 27 series with 578 patients were included; 41.9% of patients were neonates, 45.0% of patients were infants, and 13.1% of patients were children. All-cause mortality was 14.0% (95% CI, 8.0%-22.0%). Overall good neurologic outcome rates were 62.0% (95% CI, 57.0%-67.0%). Overall poor neurologic outcome rates were 21.0% (95% CI, 17.0%-26.0%). Neonates were significantly less likely to have good neurologic outcomes than infants (48.0%; 95% CI, 35.0%-62.0% versus 77.0%; 95% CI, 70.0%-84.0%; P < .01). Treatment indications following the Bicêtre neonatal evaluation score resulted in significantly higher rates of good neurologic outcome (P = .04). Patients with congestive heart failure had significantly lower rates of good neurologic outcome (OR, 0.50; 95% CI, 0.28-0.88; P = .01). LIMITATIONS: Limitations were selection and publication biases. CONCLUSIONS: Patients receiving endovascular embolization of vein of Galen malformations experienced good long-term clinical outcomes in >60% of cases. Appropriate patient selection is key as treatment guided by the Bicêtre neonatal evaluation score was associated with improved neurologic outcomes.
BACKGROUND: Outcomes after endovascular embolization of vein of Galen malformations remain relatively poorly described. PURPOSE: We performed a systematic review of the literature to determine outcomes and predictors of good outcomes following endovascular treatment of vein of Galen malformations. DATA SOURCES: We used Ovid MEDLINE, Ovid Embase, and the Web of Science. STUDY SELECTION: Our study consisted of all case series with ≥4 patients receiving endovascular treatment of vein of Galen malformations published through January 2017. DATA ANALYSIS: We studied the following outcomes: complete/near-complete occlusion rates, technical complications, perioperative stroke, perioperative hemorrhage, technical mortality, all-cause mortality, poor neurologic outcomes, and good neurologic outcomes. Outcomes were stratified by age-group (neonate, infant, child). A random-effects meta-analysis was performed. DATA SYNTHESIS: A total of 27 series with 578 patients were included; 41.9% of patients were neonates, 45.0% of patients were infants, and 13.1% of patients were children. All-cause mortality was 14.0% (95% CI, 8.0%-22.0%). Overall good neurologic outcome rates were 62.0% (95% CI, 57.0%-67.0%). Overall poor neurologic outcome rates were 21.0% (95% CI, 17.0%-26.0%). Neonates were significantly less likely to have good neurologic outcomes than infants (48.0%; 95% CI, 35.0%-62.0% versus 77.0%; 95% CI, 70.0%-84.0%; P < .01). Treatment indications following the Bicêtre neonatal evaluation score resulted in significantly higher rates of good neurologic outcome (P = .04). Patients with congestive heart failure had significantly lower rates of good neurologic outcome (OR, 0.50; 95% CI, 0.28-0.88; P = .01). LIMITATIONS: Limitations were selection and publication biases. CONCLUSIONS:Patients receiving endovascular embolization of vein of Galen malformations experienced good long-term clinical outcomes in >60% of cases. Appropriate patient selection is key as treatment guided by the Bicêtre neonatal evaluation score was associated with improved neurologic outcomes.
Authors: P L Lasjaunias; H Alvarez; G Rodesch; R Garcia-Monaco; K Ter Brugge; P Burrows; W Taylor Journal: Interv Neuroradiol Date: 2001-05-15 Impact factor: 1.610
Authors: Maggie L Chow; Daniel L Cooke; Heather J Fullerton; Matthew R Amans; Jared Narvid; Christopher F Dowd; Randall T Higashida; Van V Halbach; Steven W Hetts Journal: J Neurointerv Surg Date: 2014-04-30 Impact factor: 5.836
Authors: Alex Berenstein; Johanna T Fifi; Yasunari Niimi; Salvatore Presti; Rafael Ortiz; Saadi Ghatan; Barak Rosenn; Michelle Sorscher; Walter Molofsky Journal: Neurosurgery Date: 2012-05 Impact factor: 4.654
Authors: P Lasjaunias; F Hui; M Zerah; R Garcia-Monaco; V Malherbe; G Rodesch; A Tanaka; H Alvarez Journal: Childs Nerv Syst Date: 1995-02 Impact factor: 1.475
Authors: Gregory G Heuer; Brandon Gabel; Lauren A Beslow; Michael F Stiefel; Erin S Schwartz; Phillip B Storm; Rebecca N Ichord; Robert W Hurst Journal: Childs Nerv Syst Date: 2010-01-05 Impact factor: 1.475
Authors: Luis Fernando Pulido; Diana Murcia Salazar; Diego Gómez Amarillo; Juan Nicolás Useche; Kemel A Ghotme Journal: Childs Nerv Syst Date: 2021-02-17 Impact factor: 1.475
Authors: Cody Savage; Andrew T Hale; Matthew S Parr; Alexander Hedaya; Benjamin W Saccomano; Georges Bouobda Tsemo; Muhammad U Hafeez; Omar Tanweer; Peter Kan; Laurent J Solomon; Dan Meila; Peter B Dirks; Jeffrey P Blount; James M Johnston; Brandon G Rocque; Curtis J Rozzelle; Kartik Bhatia; Prakash Muthusami; Timo Krings; Jesse Jones Journal: Front Pediatr Date: 2022-09-30 Impact factor: 3.569
Authors: Christian Paul Stracke; Lukas Meyer; Wolfram Schwindt; Alexander Ranft; Ronald Straeter Journal: Front Neurol Date: 2022-02-22 Impact factor: 4.003